COVID-19 vaccines for patients with cancer: benefits likely outweigh risks
Autor: | Joyce K. Hwang, Andrew Z. Wang, Zihai Li, Tian Zhang |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
Patients with cancer and COVID-19 Cancer Research medicine.medical_specialty Coronavirus disease 2019 (COVID-19) medicine.medical_treatment COVID-19 vaccines Antineoplastic Agents Review Malignancy lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine Neoplasms Pandemic Animals Humans Medicine Intensive care medicine Adverse effect Pandemics Molecular Biology business.industry COVID-19 and cancer lcsh:RC633-647.5 Vaccination Cancer COVID-19 Hematology Immunotherapy lcsh:Diseases of the blood and blood-forming organs medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Clinical trial SARS-CoV-2 virus vaccines Cancer therapies 030104 developmental biology Oncology 030220 oncology & carcinogenesis business |
Zdroj: | Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-11 (2021) Journal of Hematology & Oncology |
ISSN: | 1756-8722 |
Popis: | Less than a year since the start of the COVID-19 pandemic, ten vaccines against SARS-CoV-2 have been approved for at least limited use, with over sixty others in clinical trials. This swift achievement has generated excitement and arrives at a time of great need, as the number of COVID-19 cases worldwide continues to rapidly increase. Two vaccines are currently approved for full use, both built on mRNA and lipid nanotechnology platforms, a success story of mRNA technology 20 years in the making. For patients with cancer, questions arise around the safety and efficacy of these vaccines in the setting of immune alterations engendered by their malignancy and/or therapies. We summarize the current data on leading COVID-19 vaccine candidates and vaccination of patients undergoing immunomodulatory cancer treatments. Most current cancer therapeutics should not prevent the generation of protective immunity. We call for more research in this area and recommend that the majority of patients with cancer receive COVID vaccinations when possible. |
Databáze: | OpenAIRE |
Externí odkaz: |